Non-small cell lung cancer (NSCLC)
Conditions
Interventions
Observation group:None
Sponsors
The Second Affiliated Hospital of Harbin Medical University
Eligibility
Sex/Gender
All
Age
14 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients with advanced solid tumors confirmed by histology; 2. Age 14 years; 3. Presence of at least one measurable target lesion to demonstrate drug response according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1); 4. Patients receiving combined treatment with anlotinib and anti-PD-1 inhibitors; 5. Eastern Cooperative Oncology Group performance status (ECOG PS) of <=2.
Exclusion criteria
Exclusion criteria: 1. Previous use of Anlotinib; 2. Patients with clinically active brain metastases; 3. Patients with active autoimmune diseases or a history of autoimmune diseases; 4. Accompanied by another serious disease that may threaten the patient's survival, such as severe cerebrovascular disease, acute myocardial infarction, and advanced liver cirrhosis; 5. Efficacy evaluation data not available;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| progression free survival; | — |
Countries
China
Contacts
Public ContactDan Lu
The Second Affiliated Hospital of Harbin Medical University
Outcome results
None listed